Clinical TrialJul 2, 2026, 09:06 AM
Myriad Genetics Prolaris Test Data Shows Strong Prognostic Value
AI Summary
Myriad Genetics announced new published data from the largest individual-patient-data meta-analysis of its Prolaris Biopsy Test. The study, published in Clinical Genitourinary Cancer, involved 8,478 patients and demonstrated that Prolaris adds significant prognostic information beyond conventional clinical risk categories for localized prostate cancer. This evidence supports Prolaris's role in risk stratification, helping clinicians identify appropriate candidates for active surveillance, treatment, or treatment escalation by providing insight into disease progression risk.
Key Highlights
- Myriad Genetics announced new published data from the largest individual-patient-data meta-analysis of its Prolaris Biopsy Test.
- The meta-analysis included 14 studies with 8,478 patients, with individual data for 7,924 patients.
- Prolaris adds significant prognostic information beyond conventional clinical risk categories for localized prostate cancer.
- The test helps inform initial prostate cancer management discussions and shared decision-making.
- Prolaris combined clinical risk score (CCR) was prognostic for distant metastasis and prostate cancer-specific mortality.
- Findings were consistent across all NCCN risk groups and initial disease management strategies.
- The study was published in Clinical Genitourinary Cancer.
Price Impact
More from MYGN